Transarterial Chemoembolization for the Treatment of Lung Cancer

Status Recruiting

Clinical Trial Summary

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor's blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine safety and efficacy (local progression free survival) of chemoembolization of lung cancer that is chemorefractory, unresectable, and unablatable. OUTLINE: Patients receive lung chemoembolization using Lipiodol, mitomycin, and Embospheres. Response to treatment is evaluated on computed tomography (CT) scans. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05672108
Study type	Interventional
Source	City of Hope Medical Center
Contact
Status	Recruiting
Phase	Phase 2
Start date	May 12, 2023
Completion date	October 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04989283` - Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer	Phase 2
Recruiting	`NCT05106374` - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Terminated	`NCT03707925` - Bronchoscopic Laser Ablation of Peripheral Lung Tumors	N/A
Active, not recruiting	`NCT04013542` - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Phase 1
Not yet recruiting	`NCT06427369` - An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer	Phase 1
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Recruiting	`NCT04073745` - Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT05830058` - Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT03637816` - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer	Phase 2/Phase 3
Recruiting	`NCT04298606` - A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence	Early Phase 1
Recruiting	`NCT05802186` - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study	N/A
Recruiting	`NCT06122064` - A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer	N/A
Recruiting	`NCT03634241` - Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study	Phase 2
Recruiting	`NCT04314401` - National Cancer Institute "Cancer Moonshot Biobank"
Recruiting	`NCT05493566` - Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer	Early Phase 1
Suspended	`NCT05501665` - Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	Phase 1/Phase 2
Withdrawn	`NCT04061590` - Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT06225427` - Gilteritinib for the Treatment of ALK NSCLC	Phase 1
Withdrawn	`NCT04085081` - Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers	N/A
Active, not recruiting	`NCT03939481` - Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer